The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Gene Therapy For Parkinson’s Disease Market By 2030 Based On Its 2026 Value?
The gene therapy for parkinson’s disease market has witnessed substantial growth in recent years. This market is projected to expand from $0.64 billion in 2025 to $0.81 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 26.3%. Historically, this growth can be attributed to progress in viral vector engineering, an enhanced understanding of Parkinson’s disease pathology, increased funding for neuroscience research, the introduction of improved delivery technologies, and positive early clinical trial outcomes.
The gene therapy for parkinson’s disease market is projected to experience significant expansion in the coming years. It is expected to reach a value of $2.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.0%. This projected growth throughout the forecast period is driven by factors such as increasing investments in neurodegenerative disease therapies, a rising adoption of personalized gene therapy approaches, the expansion of late-stage clinical pipelines, a growing demand for disease-modifying treatments, and the advancement of minimally invasive delivery techniques. Prominent trends for the forecast period encompass the increasing development of viral vector-based therapies, a heightened focus on dopamine restoration approaches, the expanding use of neurotrophic factor gene delivery, the broadening of precision intracerebral delivery methods, and an enhanced emphasis on long-term therapeutic efficacy.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp
Which Major Factors Are Contributing To The Development Of The Gene Therapy For Parkinson’s Disease Market?
The gene therapy for Parkinson’s disease market is anticipated to expand due to the increasing focus on personalized medicine. Personalized medicine refers to a medical approach that customizes treatment and prevention plans according to an individual’s unique genetic profile, lifestyle, and environment. Interest in personalized medicine is escalating because of the rising demand for targeted interventions that enhance treatment effectiveness while minimizing adverse side effects. In the context of gene therapy for Parkinson’s disease, personalized medicine is utilized to deliver specific genetic modifications designed to restore dopamine function and address individual patient-specific disease mechanisms. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, marking a significant increase from the 6 approvals granted in 2022. Thus, the growing interest in personalized medicine is driving the growth of the gene therapy for Parkinson’s disease market.
How Are Different Segment Groups Identified Within The Gene Therapy For Parkinson’s Disease Market?
The gene therapy for parkinson’s disease market covered in this report is segmented –
1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy
2) By Vector Type: Viral Vectors, Non-Viral Vectors
3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes
4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors
2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy
Which Trends Are Expected To Shape The Gene Therapy For Parkinson’s Disease Market?
Leading companies within the gene therapy for Parkinson’s disease market are concentrating on creating more precise therapies, like regenerative medicine advanced therapy, to boost neuronal survival, restore dopamine function, and deliver lasting disease-modifying advantages for those with Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) signifies a specific United States Food and Drug Administration (FDA) designation awarded to regenerative medicine products, such as cell therapies, gene therapies, and tissue-engineered products, which aim to treat, modify, reverse, or cure serious or life-threatening illnesses. For instance, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy company, introduced AB-1005, an investigational AAV2-GDNF gene therapy that acquired FDA regenerative medicine advanced therapy (RMAT) designation. This designation, designed to speed up the development and review of promising therapies, was awarded based on data provided by AskBio, including clinical findings from its Phase Ib open-label, uncontrolled trial, demonstrating AB-1005’s potential to decelerate disease progression and improve motor function in Parkinson’s patients.
Who Are The Major Companies Operating In The Gene Therapy For Parkinson’s Disease Market?
Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.
Access The Complete Gene Therapy For Parkinson’s Disease Market Report:
Which Regional Market Leads The Gene Therapy For Parkinson’s Disease Market?
North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Gene Therapy For Parkinson’s Disease Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp
Browse Through More Reports Similar to the Global Gene Therapy For Parkinson’s Disease Market 2026, By The Business Research Company
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Anti Parkinson Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report
Nucleic Acid Based Gene Therapy Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model